Hikma Pharmaceuticals
13 Hanover Square
London
W1S 1HL
United Kingdom
Tel: 44-0-20-7399-2760
Fax: 44-0-20-7399-2761
Website: http://www.hikma.com/
Email: media@hikma.com
115 articles about Hikma Pharmaceuticals
-
California, Other States and Organizations Develop Schemes to Enter Generic Market and Drive Down...
1/10/2020
The State of California is considering a measure to sell its own brand of generic drugs in an effort to get in on those cost-savings. California’s Gov. Gavin Newsom is expected to reveal the scheme today in his new state budget. -
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
1/9/2020
Product designed to provide safer, more immediate treatment option for patients
-
Arecor and Hikma Announce Exclusive Agreement to Develop and Commercialise Ready-To-Use Medicine Using Arestat™ TechnologyProduct designed to provide safer, more immediate treatment option for patients
1/9/2020
Hikma Pharmaceuticals PLC and Arecor Ltd announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.
-
Civica Rx and Hikma Announce Shipments of Heparin and Seven Other Essential Injectable Medicines
12/10/2019
Marks first key milestone for the Civica Rx-Hikma partnership, which is set to supply 14 essential medicines to US hospitals and patients
-
Hikma Ventures leads Series A financing for development of Winterlight Labs' AI vocal technology to detect central nervous system disorders and track efficacy of treatments
11/18/2019
Hikma Pharmaceuticals PLC, announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.
-
Hikma launches prefilled syringes in the US
9/17/2019
Heparin Sodium Injection in a ready-to-use syringe is the first product using Hikma's new injectable manufacturing capability [17-September-2019] LONDON , Sept. 17, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P) the multinational pharmaceutical company, has l
-
Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US
7/23/2019
Partnership will supply 14 essential medicines to US hospitals and patients
-
Today, Civica Rx announced a five-year deal with London, UK-based Hikma Pharmaceuticals to manufacture and supply Civica’s members with 14 sterile injectable drugs as a private label distributor.
-
Despite Political Rhetoric, Some Drug Prices Jumped on July 1, Including Medicines on Shortage Lists
7/2/2019
The beginning of July is when many companies increase the price on prescription medications in the U.S. This year's price increases are higher than the same period last year. -
Hikma Ventures participates in $11 million funding round for Pillo Health
5/30/2019
Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) today announced its venture capital arm Hikma Ventures has participated in an $11 million financing round for Boston-based Pillo Health.
-
Hikma launches 100th injectable medicine in US with introduction of Vancomycin Hydrochloride for Injection, USP
5/1/2019
Hikma Pharmaceuticals PLC launched its 100th injectable medicine in the United States with the introduction of Vancomycin Hydrochloride for Injection, USP, 5g, 10g and 750mg, through its US affiliate, Hikma Pharmaceuticals USA Inc.
-
Biolinq Expands Series A Financing With $4.75 Million Investment
3/28/2019
Biolinq announced it has expanded its oversubscribed Series A financing with an additional investment of $4.75 million led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.
-
Hikma establishes partnership with Melinta in MENA
2/28/2019
Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela
-
Pharmaceutical companies traditionally adjust the price of drugs twice a year, so it wouldn’t normally be a hot topic. But drug prices have been a controversial subject for several years, especially in politics.
-
Although the dominant story in biopharma patent litigation was the federal appeals court backing the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University over the University of California (UC) on CRISPR patents, there have been other patent decisions of note t...
-
Hikma Pharmaceuticals Appoints Kristy Ronco Executive Vice President, Sales and Marketing, Generics
8/16/2018
Ms. Ronco will be responsible for leading Generics’ retail sales, addiction therapy sales and branded sales teams.
-
Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients
7/18/2018
Leading Generic Pharmaceutical Company Increases Manufacturing Capacity to Produce and Release Significant Quantities of Scarce Medicines
-
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
-
Hikma Reaches Licensing Agreement With Celltrion for Third Biosimilar Product in the Middle East and North Africa
12/19/2017
Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima, Remsima and Herzuma - in all its MENA markets.
-
Hikma Jacks Up Price Of U.S. Drugs By 430%
8/21/2017